Dr. Biran on the Results of an Arm of the STOMP Trial in R/R Multiple Myeloma

Noa Biran, MD, associate professor of medicine, Hackensack University School of Medicine, physician, Myeloma Division, John Theurer Cancer Center, Hackensack Meridian Health, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial (NCT02343042) evaluating selinexor (Xpovio), dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone (XPd-40 vs XPd-60, respectively) in relapsed/refractory multiple myeloma.

The results of the study, which were presented during the 2021 ASH Annual Meeting, showed that the toxicity profiles of XPd-40 vs XPd-60 were comparable in terms of hematologic and nonhematologic toxicities, Biran adds. Moreover, thrombocytopenia, fatigue, and nausea were commonly observed toxicities with the regimens, Biran explains.

Regarding efficacy, the overall response rate was 65% with XPd-60, which included was the recommended phase 2 dose of selinexor, compared with 42% with XPd-40, Biran continues. As such, XPd-60 represents an exciting regimen that demonstrated activity in patients with relapsed/refractory multiple myeloma, including those with triple-class refractory disease, Biran says.